Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Cracking The Code: Understanding Analyst Reviews For AtriCure

In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 2 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 3 2 0 0 0
3M Ago 0 0 0 0 0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.0, a high estimate of $61.00, and a low estimate of $36.00. This upward trend is evident, with the current average reflecting a 15.89% increase from the previous average price target of $38.83.

Investigating Analyst Ratings: An Elaborate Study

The standing of AtriCure among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
William Plovanic Canaccord Genuity Raises Buy $61.00 $53.00
William Plovanic Canaccord Genuity Raises Buy $53.00 $49.00
Suraj Kalia Oppenheimer Raises Outperform $36.00 $32.00
Robbie Marcus JP Morgan Raises Overweight $40.00 $30.00
Danielle Antalffy UBS Raises Buy $40.00 $35.00
Mike Matson Needham Raises Buy $40.00 $34.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AtriCure compared to the broader market.
  • Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This examination reveals shifts in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AtriCure's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on AtriCure analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering AtriCure: A Closer Look

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Financial Insights: AtriCure

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: AtriCure displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 17.93%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: AtriCure's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6.78%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.69%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): AtriCure's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.3%, the company may face hurdles in achieving optimal financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.

Understanding the Relevance of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.